西部中医药
西部中醫藥
서부중의약
GANSU JOURNAL OF TRADITIONAL CHINESE MEDICINE
2014年
9期
97-98,99
,共3页
严文有%李有成%赵斌庆%王志超
嚴文有%李有成%趙斌慶%王誌超
엄문유%리유성%조빈경%왕지초
咳嗽变异性哮喘%LTB4%IL-4%姜卿金沸草散
咳嗽變異性哮喘%LTB4%IL-4%薑卿金沸草散
해수변이성효천%LTB4%IL-4%강경금비초산
cough variant asthma%LTB4%IL-4%JiangQing JinFei Cao powder
目的：观察僵卿金沸草散治疗咳嗽变异性哮喘的临床疗效及其对血清中LTB4、IL-4表达的影响。方法：将咳嗽变异性哮喘患者60例随机分为2组各30例，治疗组口服僵卿金沸草散治疗：对照组口服孟鲁司特、酮替芬治疗。观察2组患者用药前后症状、体征变化情况并检测LTB4、IL-4的表达水平。结果：治疗组显效22例，有效6例，无效2例，总有效率93.33%，对照组显效20例，有效6例，无效4例，总有效率86.67%，治疗组临床疗效优于对照组；LTB4、IL-42组治疗前比较差异无统计学意义（P＞0.05），治疗后组内比较差异显著（P＜0.01）。结论：僵卿金沸草散治疗咳嗽变异性哮喘，可能通过抑制LTB4、IL-4的表达水平，维持Th1/Th2平衡，从而控制气道炎症，减少咳嗽变异性哮喘的发作，疗效优于孟鲁司特、酮替芬。
目的：觀察僵卿金沸草散治療咳嗽變異性哮喘的臨床療效及其對血清中LTB4、IL-4錶達的影響。方法：將咳嗽變異性哮喘患者60例隨機分為2組各30例，治療組口服僵卿金沸草散治療：對照組口服孟魯司特、酮替芬治療。觀察2組患者用藥前後癥狀、體徵變化情況併檢測LTB4、IL-4的錶達水平。結果：治療組顯效22例，有效6例，無效2例，總有效率93.33%，對照組顯效20例，有效6例，無效4例，總有效率86.67%，治療組臨床療效優于對照組；LTB4、IL-42組治療前比較差異無統計學意義（P＞0.05），治療後組內比較差異顯著（P＜0.01）。結論：僵卿金沸草散治療咳嗽變異性哮喘，可能通過抑製LTB4、IL-4的錶達水平，維持Th1/Th2平衡，從而控製氣道炎癥，減少咳嗽變異性哮喘的髮作，療效優于孟魯司特、酮替芬。
목적：관찰강경금비초산치료해수변이성효천적림상료효급기대혈청중LTB4、IL-4표체적영향。방법：장해수변이성효천환자60례수궤분위2조각30례，치료조구복강경금비초산치료：대조조구복맹로사특、동체분치료。관찰2조환자용약전후증상、체정변화정황병검측LTB4、IL-4적표체수평。결과：치료조현효22례，유효6례，무효2례，총유효솔93.33%，대조조현효20례，유효6례，무효4례，총유효솔86.67%，치료조림상료효우우대조조；LTB4、IL-42조치료전비교차이무통계학의의（P＞0.05），치료후조내비교차이현저（P＜0.01）。결론：강경금비초산치료해수변이성효천，가능통과억제LTB4、IL-4적표체수평，유지Th1/Th2평형，종이공제기도염증，감소해수변이성효천적발작，료효우우맹로사특、동체분。
Objective:To explore curative effects of JiangQing JinFei Cao powder in the treatment for cough variant asthma and its influence on the expressions of LTB4 and IL-4. Methods:Sixty patients were randomized into two groups, 30 cases of the treatment group took JiangQing JinFei Cao powder, the control group montelukast and ketotifen. Syinptom and body signs of the patients in both groups were observed before and after administration, the expressions of LTB4 and IL-4 were detected. Results:In the treatment group, there were 22 cases markedly effec-tive, six cases effective, two cases ineffective, and total effective rate 93.33%, there were 20 cases markedly effec-tive, six cases effective, four cases ineffective, and total effective rate 86.67%, clinical effects of the treatment group were superior to these of the control group;the difference had no statistical meaning in the comparison of LTB4 and IL-4 before treating (P>0.05), the difference was significant in the comparison within one group after treating (P<0.01). Conclusion:JiangQing JinFei Cao powder is superior to montelukast and ketotifen for cough variant asthma, it could control the inflammation of air passage and reduce the attack of cough variant asthma, which might be through inhibiting the expressions of LTB4 and IL-4, maintaining the balance between Th1/Th2.
